title: A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients.
abstract: We compared the combination of teicoplanin plus ciprofloxacin with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients. A favourable clinical response rate was achieved in 28/38 (74%) patients receiving teicoplanin plus ciprofloxacin and in 17/35 (49%) of those receiving gentamicin plus piperacillin (P = 0.05). Microbiologically documented infections accounted for 55% of febrile events. When these episodes were analysed separately, response to teicoplanin plus ciprofloxacin remained unchanged at 74% whereas only 35% patients responded to gentamicin and pieracilin (P = 0.034). Gram-positive organisms accounted for 78% bacterial isolates with Staphylococcus epidermidis the most common pathogen. Ten out of 12 (83%) Staph. epidermidis infections resolved when treated with teicoplanin and ciprofloxacin as compared with a response rate of only two out of eight (25%) with gentamicin and piperacillin (P = 0.032). The combination of teicoplanin and ciprofloxacin was associated with no severe drug-related adverse events; by contrast, two patients receiving gentamicin plus piperacilin were withdrawn owing to adverse drug reactions, one with acute renal failure and one following a severe allergic reaction to piperacillin. We conclude that teicoplanin with ciprofloxacin is more effective than gentamicin plus piperacillin for the empirical treatment of febrile neutropenic patients. The high incidence of Gram-positive infection in our unit probably justifies the use of a specific anti-Gram-positive agent in the first-line antibiotic regimen.
authors: Department of Haematology, London Hospital, Whitechapel.
authors: S M
authors: SM
authors: Kelsey
authors: P W
authors: PW
authors: Collins
authors: C
authors: C
authors: Delord
authors: B
authors: B
authors: Weinhard
authors: A C
authors: AC
authors: Newland
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D016026:Bone Marrow Transplantation; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005334:Fever / Q000188:drug therapy* / Q000382:microbiology; D005839:Gentamicins / Q000627:therapeutic use*; D006020:Glycopeptides / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D009503:Neutropenia / Q000150:complications; D010878:Piperacillin / Q000627:therapeutic use*; D011446:Prospective Studies; D017334:Teicoplanin
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D006020:Glycopeptides; D002939:Ciprofloxacin; D017334:Teicoplanin; D010878:Piperacillin